Tumblr Yahoos: Old ...
Health Care: Drugs
Northwest Biotherapeutics Inc. (NWBO: OTC)
$3.70 -0.01 | -0.27%
05/20/13 - 04:00 PM ET
158.58K / 159.70K
Vol / Avg. Vol:3.80 / 3.71
Open / Prev. Close:3.67 - 3.80
Today's Range:2.92 - 20.00
52 Wk Range:18.93%
Performance YTD:TheStreet Rating:
Portfolios with NWBO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
Latest NWBO Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 03.07.13 | 01:03 pm
- Why Seeking Alpha's Larry Smith Is Wrong Again About Northwest Bio. 02.21.13 | 09:02 am
- Biotech Stock Mailbag: Northwest Bio, Amarin, Titan Pharma 02.15.13 | 06:02 am
- Feuerstein's Biotech-Stock Mailbag 08.04.07 | 10:08 am
Press Releases for NWBO
- NW Bio Announces That Another Brain Cancer Patient From Phase I/II DCVax®-L Trials Has Surpassed Ten-Year Cancer-Free Survival - PR Newswire 04.18.13 | 08:04 am
- NW Bio Announces $10 Million Registered Direct Offering - PR Newswire 04.18.13 | 08:04 am
- NW Bio's Phase III Trial With DCVax®-L For Brain Cancer "Adopted" As A National Priority Trial In UK - PR Newswire 04.16.13 | 08:04 am
- NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference - PR Newswire 03.19.13 | 08:03 am
- NW Bio Receives U.S. Patent On Broad Processes For Producing More Potent Dendritic Cells - PR Newswire 03.18.13 | 08:03 am
- NW Bio Establishes Cross-Border Manufacturing And Distribution For DCVax® In Europe - PR Newswire 03.12.13 | 08:03 am
- DCVax®-Direct Phase I/II Trial For All Inoperable Solid Tumors Is Expected To Produce Ongoing Results In 2013 - PR Newswire 03.05.13 | 08:03 am
- NW Bio Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe - PR Newswire 02.15.13 | 08:02 am
- NW Bio To Present At 15th Annual BIO CEO & Investor Conference - PR Newswire 02.11.13 | 08:02 am
- NW Bio Presenting At Phacilitate Cell Therapy Forum - PR Newswire 01.29.13 | 08:01 am
Partner Headlines for NWBO
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
